[go: up one dir, main page]

MX2016008499A - Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc). - Google Patents

Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).

Info

Publication number
MX2016008499A
MX2016008499A MX2016008499A MX2016008499A MX2016008499A MX 2016008499 A MX2016008499 A MX 2016008499A MX 2016008499 A MX2016008499 A MX 2016008499A MX 2016008499 A MX2016008499 A MX 2016008499A MX 2016008499 A MX2016008499 A MX 2016008499A
Authority
MX
Mexico
Prior art keywords
sultam derivatives
aryl
rorc modulators
rorc
modulators
Prior art date
Application number
MX2016008499A
Other languages
English (en)
Inventor
Bodil Van Niel Monique
Fauber Benjamin
Rene Olivier
Gaines Simon
Gobbi Alberto
Vesey David
Ward Stuart
Gancia Emanuela
LADDYWAHETTY Tammy
Winship Paul
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016008499A publication Critical patent/MX2016008499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I: (ver Fórmula) o sales farmacéuticamente aceptables de los mismos, en donde m, n, p, q, r, A, W, X1. X2. X3. X4. Y, Z, R1. R2. R3. R4. R5. R6. R7. R8. R9. R10. R11 y R12 son tal como se define en la presente descripción. Se dan a conocer además métodos de preparación de los compuestos y la utilización de los compuestos para el tratamiento de enfermedades inflamatorias tales como artritis.
MX2016008499A 2014-01-10 2015-01-09 Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc). MX2016008499A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925845P 2014-01-10 2014-01-10
US201462091063P 2014-12-12 2014-12-12
PCT/EP2015/050294 WO2015104356A1 (en) 2014-01-10 2015-01-09 ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Publications (1)

Publication Number Publication Date
MX2016008499A true MX2016008499A (es) 2016-09-13

Family

ID=52339138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008499A MX2016008499A (es) 2014-01-10 2015-01-09 Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).

Country Status (11)

Country Link
US (2) US20150197529A1 (es)
EP (1) EP3092238B1 (es)
JP (1) JP6458040B2 (es)
KR (1) KR20160106708A (es)
CN (1) CN105916852B (es)
CA (1) CA2932888A1 (es)
ES (1) ES2760521T3 (es)
MX (1) MX2016008499A (es)
RU (1) RU2016131345A (es)
TW (1) TW201620884A (es)
WO (1) WO2015104356A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620884A (zh) 2014-01-10 2016-06-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
WO2015104354A1 (en) * 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
US9481683B2 (en) * 2014-06-09 2016-11-01 University Of Notre Dame Du Lac 1,3-benzothiazinone sulfoxide and sulfone compounds
JP2017537966A (ja) * 2014-12-17 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのヘテロアリールアルキレンアリールスルタム誘導体
HK1248682A1 (zh) * 2015-05-04 2018-10-19 F. Hoffmann-La Roche Ag 作为rorc调节剂的哒嗪衍生物
HK1250235A1 (zh) 2015-07-08 2018-12-07 F. Hoffmann-La Roche Ag 作为rorc调节剂的芳基磺内酰胺衍生物
WO2017005668A1 (en) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2017102796A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
KR20190070985A (ko) * 2016-11-01 2019-06-21 에프. 호프만-라 로슈 아게 RORc 조절제로서의 피리다진 유도체
CN106966912B (zh) * 2017-04-01 2019-07-02 沧州那瑞化学科技有限公司 (r)-3-氨基丁醇的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2013064231A1 (en) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
US20130190356A1 (en) * 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
AR092348A1 (es) * 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
HK1220976A1 (zh) * 2013-06-21 2017-05-19 F. Hoffmann-La Roche Ag 作为rorc调节剂的芳基磺内酰胺衍生物
MX2016008780A (es) 2014-01-10 2016-09-08 Hoffmann La Roche Derivados de sultam heteroarilo como moduladores del receptor huerfano relacionado con el acido retinoico gamma (ror gamma).
TW201620884A (zh) 2014-01-10 2016-06-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
WO2015104354A1 (en) 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Also Published As

Publication number Publication date
US20150197529A1 (en) 2015-07-16
US20160168141A1 (en) 2016-06-16
JP6458040B2 (ja) 2019-01-23
CA2932888A1 (en) 2015-07-16
RU2016131345A (ru) 2018-02-16
JP2017502065A (ja) 2017-01-19
EP3092238A1 (en) 2016-11-16
US9751873B2 (en) 2017-09-05
TW201620884A (zh) 2016-06-16
WO2015104356A1 (en) 2015-07-16
EP3092238B1 (en) 2019-10-02
CN105916852B (zh) 2020-04-24
KR20160106708A (ko) 2016-09-12
ES2760521T3 (es) 2020-05-14
CN105916852A (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
PH12014502788A1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
MX2016008499A (es) Derivados de arilsultamo como moduladores del receptor huerfano relacionado con el receptor de retinoide (rorc).
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
CY1124170T1 (el) Ενωσεις 1-κυανο-πυρρολιδινης ως αναστολεις usp30
TW201613872A (en) IRAK4 inhibiting agents
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MA39749A (fr) Dérivés de pipéridine-dione
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
MX2015006926A (es) Derivados de bencil sulfonamida como moduladores del receptor huerfano relacionado con el receptor retinoide (rorc).
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
PH12021551134A1 (en) Oxysterols and methods of use thereof
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
PH12018500061A1 (en) Oxysterols and methods of use thereof
TN2014000436A1 (en) Inhibitors of platelet aggregation
PH12017501523A1 (en) Selective bace1 inhibitors
MX2015011180A (es) Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc).
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2016008721A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc).
MX2015015614A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc).
TW201613864A (en) Novel compounds
PH12017500095A1 (en) Imidazopyridazine compounds
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
ZA201606471B (en) Antimitotic amides for the treatment of cancer and proliferative disorders